Data-independent acquisition mass spectrometry in severe rheumatic heart disease (RHD) identifies a proteomic signature showing ongoing inflammation and effectively classifying RHD cases
Publication Date
2022Author
M Taariq Salie, Jing Yang, Carlos R Ramírez Medina, Liesl J Zühlke, Chishala Chishala, Mpiko Ntsekhe, Bernard Gitura, Stephen Ogendo, Emmy Okello, Peter Lwabi, John Musuku, Agnes Mtaja, Christopher Hugo-Hamman, Ahmed El-Sayed, Albertino Damasceno, Ana Mocumbi, Fidelia Bode-Thomas, Christopher Yilgwan, Ganiyu A Amusa, Esin Nkereuwem, Gasnat Shaboodien, Rachael Da Silva, Dave Chi Hoo Lee, Simon Frain, Nophar Geifman, Anthony D Whetton, Bernard Keavney, Mark E Engel
Metadata
Show full item recordAbstract/ Overview
Background
Rheumatic heart disease (RHD) remains a major source of morbidity and mortality in developing countries. A deeper insight into the pathogenetic mechanisms underlying RHD could provide opportunities for drug repurposing, guide recommendations for secondary penicillin prophylaxis, and/or inform development of near-patient diagnostics.
Methods
We performed quantitative proteomics using Sequential Windowed Acquisition of All Theoretical Fragment Ion Mass Spectrometry (SWATH-MS) to screen protein expression in 215 African patients with severe RHD, and 230 controls. We applied a machine learning (ML) approach to feature selection among the 366 proteins quantifiable in at least 40% of samples, using the Boruta wrapper algorithm. The case–control differences and contribution to Area Under the Receiver Operating Curve (AUC) for each of the 56 proteins identified by the Boruta algorithm were calculated by Logistic Regression adjusted for age, sex and BMI. Biological pathways and functions enriched for proteins were identified using ClueGo pathway analyses.
Results
Adiponectin, complement component C7 and fibulin-1, a component of heart valve matrix, were significantly higher in cases when compared with controls. Ficolin-3, a protein with calcium-independent lectin activity that activates the complement pathway, was lower in cases than controls. The top six biomarkers from the Boruta analyses conferred an AUC of 0.90 indicating excellent discriminatory capacity between RHD cases and controls.
Conclusions
These results support the presence of an ongoing inflammatory response in RHD, at a time when severe valve disease has developed, and distant from previous episodes of acute rheumatic fever. This biomarker signature could have potential utility in recognizing different degrees of ongoing inflammation in RHD patients, which may, in turn, be related to prognostic severity.